The reason some cancer treatments stop working

Scientist examining samples under a microscope in a laboratory

Your immune system may be sabotaging your cancer treatment from the inside, and scientists just found the switch responsible.

Quick Take

A protein called SLAMF6 acts like a built-in brake on the immune cells that fight cancer, causing them to burn out before the job is done.
Blocking SLAMF6 with antibodies boosted T cell activity and slowed tumor growth in lab and animal studies.
The research could explain why some patients stop responding to immunotherapy drugs that already work well for others.
No human clinical trials have confirmed these results yet, so the findings are promising but not proven.

The Immune Cells That Fight Cancer Are Wearing Themselves Out

Your body has specialized immune cells called T cells. Their job is to hunt and kill cancer cells. The problem is that tumors are patient. Over time, T cells that keep fighting without a break become exhausted. They weaken, lose their killing power, and stop making fresh, strong copies of themselves. This is one of the main reasons cancer comes back even after treatment seems to be working. ^[1]

Researchers have known about T cell exhaustion for years. What they did not fully understand was why it happens so reliably, even in patients receiving powerful immunotherapy drugs. A protein sitting right on the surface of T cells turns out to be a key part of the answer. ^[2]

SLAMF6 Is the Hidden Brake Slowing Your Immune System Down

The protein is called SLAMF6. It sits on the surface of T cells and interacts with itself, meaning it binds to the same protein on a neighboring T cell. That interaction sends an internal signal that dials down the T cell’s activity. Researchers describe it as a built-in brake. ^[3] The 2026 Nature study found that this self-binding happens independently of the tumor itself, which means the brake is always on, no matter what the cancer is doing. ^[3]

SLAMF6 is found most heavily on a specific type of exhausted T cell called a progenitor or stem-like exhausted T cell. ^[3] These are the cells that could, in theory, keep generating new fighters. When SLAMF6 suppresses them, the immune system loses its ability to sustain a long-term attack. That is the core of the problem researchers are now trying to solve. ^[2]

Blocking SLAMF6 Woke Up Exhausted T Cells in the Lab

Scientists tested antibodies designed to block SLAMF6 from binding to itself. In mouse models, those antibodies strongly boosted T cell activity, cut the number of exhausted T cells, and slowed tumor growth. ^[3] An earlier eLife study found that T cells without SLAMF6 killed melanoma cells more effectively and produced longer-lasting tumor remission in animal models. ^[2] A separate study published in Nature Communications found that blocking SLAMF6 on leukemia cells triggered T cells to attack and kill those cells both in lab dishes and in humanized animal models. ^[5]

MD Anderson Cancer Center researchers reported that anti-SLAMF6 treatment corrected T cell dysfunction and reduced tumor burden while increasing the cells’ ability to fight back. ^[4] Across multiple research groups and cancer types, the pattern is consistent: remove the SLAMF6 brake, and T cells fight harder and longer. That kind of convergence across labs and cancer types is exactly what moves a target up the priority list.

Real Promise, But No Human Proof Yet

Here is the honest part that most headlines skip. Every study cited above used mouse models, lab assays, or humanized animal systems. Not one completed randomized human trial has confirmed these results in real patients. ^[2]^[3]^[5] The Nature abstract itself admits that SLAMF6’s role “remains ambiguous” because the protein has both activating and inhibitory effects depending on context. ^[3] That is not a reason to dismiss the research. It is a reason to wait for the next step before declaring victory.

The research also does not yet show what happens to patients over time. Metrics like progression-free survival and overall survival, the numbers that actually matter to a patient, are not in the current record. ^[2]^[3]^[4] There is also no published safety data on what happens when you block SLAMF6 in a living human being. Could it trigger autoimmune problems? Could it disrupt immune balance? Those questions need answers before any drug reaches patients. The science is real and the logic is sound. But the distance between a promising lab finding and a treatment that helps people is longer than most headlines suggest.